Monitoring the metabolic side-effects of atypical antipsychotics

Psychiatrist

Volumn 34, Issue 9, 2010, Pages 390-395

  Gumber, Rohit ^a   Abbas, Mizrab ^a   Minajagi, Manjunath ^a  

^a LEICESTERSHIRE PARTNERSHIP NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; METABOLIC PARAMETERS; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RISK ASSESSMENT;

EID: 77956936548     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.109.027433     Document Type: Article

References (12)

1. De Hert M, Hanssens L, Van Winkel R, Wampers M, Van Eyck D, Scheen A, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007; 33: 823-30. (Pubitemid 47343707)
2. Prescribing Observatory for Mental Health (POMH-UK). The Metabolic Side Effects of Antipsychotic Medication Represent a Serious Risk to Physical Health. POMH-UK, 2006 (http://www.rcpsych.ac.uk/pdf/T2%20info%20leaflet.pdf).
3. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007; 21: 357-73.
4. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obesity 2002; 26: 137-41.
5. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drugnaive patients with schizophrenia. Life Sci 2004; 74: 1999-2008.
6. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184: 58-62.
7. International Diabetes Federation (IDF). The IDF Consensus Worldwide Definition of Metabolic Syndrome. IDF, 2006 (http://www.idf.org/webdata/docs/ IDF-Meta-def-final.pdf).
8. National Library for Health. Clinical Knowledge Summaries: Schizophrenia. National Library for Health, 2007 (http://www.cks.library.nhs.uk/schizophrenia) .
9. Taylor D, Paton C, Kerwin R. Antipsychotics - monitoring. In The Maudsley Prescribing Guidelines (9th edn). Informa Healthcare, 2007.
10. Barnes TRE, Paton C, Cavanagh MR, Hanock E, Taylor DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33: 1397-1403.
11. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166: 345-53.
12. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (CG82). NICE, 2009.